Peringatan Keamanan

Doses of up to 300 mg/day for up to 4 days have produces no observable toxic effects in humans A32775. In a chronic toxicity study, rats were given up to 200 mg/kg/day orally for 91 days with no observable toxic effects A32772.

Thonzylamine

DB11235

small molecule approved

Deskripsi

Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Struktur Molekul 2D

Berat 286.379
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

520 Data
Aclidinium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Thonzylamine.
Mirabegron The risk or severity of urinary retention can be increased when Thonzylamine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Thonzylamine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Thonzylamine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Thonzylamine.
Tiotropium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Thonzylamine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Umeclidinium.
Benzylpenicilloyl polylysine Thonzylamine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Thonzylamine.
Glycopyrronium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum toxin type A.
Glucagon Thonzylamine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Thonzylamine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Thonzylamine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Thonzylamine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Thonzylamine is combined with Ramosetron.
Amphetamine Amphetamine may decrease the sedative activities of Thonzylamine.
Phentermine Phentermine may decrease the sedative activities of Thonzylamine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Thonzylamine.
Benzphetamine Benzphetamine may decrease the sedative activities of Thonzylamine.
Diethylpropion Diethylpropion may decrease the sedative activities of Thonzylamine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Thonzylamine.
Mephentermine Mephentermine may decrease the sedative activities of Thonzylamine.
MMDA MMDA may decrease the sedative activities of Thonzylamine.
Midomafetamine Midomafetamine may decrease the sedative activities of Thonzylamine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Thonzylamine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Thonzylamine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Thonzylamine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Thonzylamine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Thonzylamine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Thonzylamine.
Metamfetamine Metamfetamine may decrease the sedative activities of Thonzylamine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Thonzylamine.
Ritobegron Ritobegron may decrease the sedative activities of Thonzylamine.
Mephedrone Mephedrone may decrease the sedative activities of Thonzylamine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Thonzylamine.
Gepefrine Gepefrine may decrease the sedative activities of Thonzylamine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Thonzylamine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Thonzylamine.
Naltrexone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Thonzylamine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Thonzylamine is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Thonzylamine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Thonzylamine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Thonzylamine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Thonzylamine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Thonzylamine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Thonzylamine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Thonzylamine is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Thonzylamine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Thonzylamine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Thonzylamine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Thonzylamine.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Thonzylamine.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Thonzylamine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Thonzylamine.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Thonzylamine.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Thonzylamine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Thonzylamine.

Target Protein

Histamine H1 receptor HRH1
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M4 CHRM4
Muscarinic acetylcholine receptor M5 CHRM5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18858080
    SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99.
  • PMID: 18888474
    AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41.
Textbook
  • ISBN: 978-1-25-958473-2
    Chapter 39: Histamine, Bradykinin, and Their Antagonists. (2018). In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.

Contoh Produk & Brand

Produk: 5 • International brands: 0
Produk
  • Nasopen PE
    Liquid • - • Oral • US • OTC
  • Poly Hist PD
    Liquid • - • Oral • US • OTC
  • Poly-Hist DM
    Liquid • - • Oral • US • OTC
  • TexaClear Kids Sinus Relief
    Liquid • - • Oral • US • OTC
  • Vanacof Ape
    Liquid • - • Oral • US • OTC

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul